This is a summary of the European public assessment report (EPAR) for Adasuve. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Adasuve.
Therapeutic Indication
Adasuve is indicated for the rapid control of mild\-to\-moderate agitation in adult patients with schizophrenia or bipolar disorder. Patients should receive regular treatment immediately after control of acute agitation symptoms.
Therapeutic Area (MeSH)
ATC Code
N05AH01
ATC Item
N/A
Pharmacotherapeutic Group
Nervous system
Active Substance (Summary)
INN / Common Names
EMA Name
Adasuve
Medicine Name
Adasuve
Aliases
N/ANo risk management plan link.
